AddedRisk Factors
•the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•the data collected from clinical trials of our product candidates may not be sufficient to obtain regulatory approval in the EU or elsewhere for the proposed indication in the proposed population; and
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•the approval policies or regulations of the EMA, the European Commission or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Any of the above events could prevent us from achieving market approval of trofinetide and could substantially increase the costs of commercializing trofinetide.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
We are currently conducting several studies with our product candidates, including our Phase 2 study evaluating the efficacy and safety of an internally-developed compound known as ACP-204, as a potential treatment for the treatment of hallucinations and delusions associated with ADP and our Phase 3 COMPASS study evaluating the efficacy and safety of ACP-101 (intranasal carbetocin) for the treatment of hyperphagia in PWS and may conduct additional studies with these and other product candidates in the future. We plan to initiate an additional Phase 2 study of ACP-204 in LBDP in the third quarter of 2025 and to initiate a Phase 2 study of ACP-711 in essential tremor in 2026.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
In September 2024, Catherine Owen Adams became our new Chief Executive Officer (CEO), replacing our former CEO, Stephen R. Davis. Our new CEO will be critical to executing on and achieving our strategy. Further, our new CEO may bring different perspectives, and the future strategy and direction of our business may differ materially from those of the past. If we are unable to execute an orderly transition and successfully integrate our new CEO into our leadership team, we may experience material disruptions to our operations and our financial condition and results of operations may be adversely affected.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
We have a history of net losses and we may not be able to predict the extent of future losses.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
We have experienced significant net losses since our inception. As of December 31, 2024, we had an accumulated deficit of approximately $2.2 billion. We expect to increase our expenses and other investments in the coming years as we fund our operations, in-licensing or acquisition opportunities, and capital expenditures. Thus, our future operating results, profitability and other financial metrics may fluctuate from period to period, and we will need to generate significant revenues to achieve and maintain profitability and/or positive cash flow on a sustained basis.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
We expect that our revenues over the next few years will be entirely dependent on our ability to generate product sales. Substantially all of our revenues since May 2016 were from U.S. net product sales of NUPLAZID and DAYBUE. To the extent that we cannot generate significant revenues from the sale of our products to cover our expenses, including the significant expenses associated with commercializing our products and continuing to develop trofinetide in additional indications and jurisdictions outside the U.S., we may not achieve profitability and/or may have to reduce our commercialization and/or research and development activities to become profitable, which would harm our future growth prospects. Additionally, to obtain revenues from our product candidates, if approved, we must succeed, either alone or with others, in developing, obtaining regulatory approval for, manufacturing and marketing compounds with significant market potential. We may never succeed in these activities and may never generate revenues that are significant enough to achieve profitability.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
pre-market approval of drugs, delays, suspension or withdrawal of approvals, seizures or recalls of products, operating restrictions, and criminal prosecutions.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
For example, on August 16, 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the ACA will be subject to additional challenges in the future. It is unclear how any such challenges and additional healthcare reform measures of the current administration will impact the ACA and our business.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
An expansion in the government’s role in the U.S. healthcare industry may increase existing congressional or governmental agency scrutiny on price increases, such as the ones we have implemented for NUPLAZID, cause general downward pressure on the prices of prescription drug products, lower reimbursements for providers using our products, reduce product utilization and adversely affect our business and results of operations. There have been several recent U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. For example, the IRA, among other things, (1) directs the U.S. Department of Health and Human Services (HHS) to negotiate the price of certain single-source drugs that have been on the market for at least 7 years covered under Medicare (the Medicare Drug Price Negotiation Program) and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. HHS has and will continue to issue and update guidance as these programs are implemented. These provisions began to take effect progressively in fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon reimbursement prices of the first ten drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. HHS will select up to fifteen additional drugs covered under Part D for negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program. On December 7, 2023, an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. Further, the overall funding of certain government programs such as Medicaid and Medicare is uncertain and there is no guarantee that funds approved by the U.S. Congress will be made available by the current administration. We expect additional health reform measures may be implemented in the future, particularly in light of the recent U.S. Presidential and Congressional elections.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
The Swiss Federal Act on Data Protection, or the FADP, also applies to the collection and processing of personal data, including health-related information, by companies located in Switzerland, or in certain circumstances, by companies located outside of Switzerland.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
Failure by our third-party manufacturers or us to comply with applicable regulations could result in sanctions being imposed on us, including shutdown of the third-party vendor or invalidation of drug product lots or processes, fines, injunctions, civil penalties, failure of regulatory authorities to grant pre-market approval of drugs, delays, suspension, variation or withdrawal of approvals, seizures or recalls of products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products, if approved, and significantly harm our business, financial condition, results of operations and prospects.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
(Patheon) We have contracted with Patheon to manufacture NUPLAZID 10 mg tablet and 34 mg capsule drug product and DAYBUE for commercial use, Catalent to manufacture NUPLAZID 34 mg drug product for commercial use in the U.S., Bend to manufacture DAYBUE for commercial use, and Halo to manufacture trofinetide DAYBUE STIX 5g, 6g, and 8g drug product stick packs for commercial use in the U.S. and Canada.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
This regulation, which entered into application on January 12, 2025 and has a phased implementation, It is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. products.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have incurred, and expect to continue to incur, significant costs as a result of laws laws, regulations and regulations standards relating to various aspects of our business, including corporate governance governance, work force initiatives and other matters. matters, and failure to comply with such laws, regulations and standards could adversely affect our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
These patients generally have life-threatening or severe illnesses for which there are no alternative therapies or they have exhausted all other available therapies. therapies, and unapproved products or product candidates may be provided to eligible patients based upon the request of healthcare professionals as allowed by country specific laws and regulations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have had several clinical studies evaluating pimavanserin that did not achieve statistical significance on certain endpoints, including the unsuccessful Phase 3 ADVANCE-2 study of pimavanserin for the treatment of the negative symptoms of schizophrenia in March 2024 and 2024, the unsuccessful Phase 2 study of pimavanserin for the treatment of irritability associated with autism spectrum disorder in pediatric populations (Pediatric Phase 2 Trial) in October 2024. 2024 and the unsuccessful Phase 3 COMPASS PWS study of intranasal carbetocin for the treatment of hyperphagia in Prader-Willi Syndrome in September 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
During times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our registration obligations under this registration rights agreement, the 2026 Registration Rights Agreement, which cover all shares securities now held or later acquired by the Baker Entities, will be in effect for up to 10 years, and include our obligation to facilitate certain underwritten public offerings and block trades of our securities by the Baker Entities in the future.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Laws Laws, regulations and regulations standards affecting public companies, various aspects of our business, including as a result of provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act that was enacted in July 2010, the provisions of the Sarbanes-Oxley Act of 2002 (SOX), and rules adopted or proposed by the SEC and by The Nasdaq Stock Market, Market and executive orders, have resulted in, and will continue to result in, significant costs to us as we evaluate the implications of these rules laws, regulations and standards and respond to their requirements.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
On May 25, 2022, we filed 23, 2025, the SEC declared effective a registration statement that we filed on May 9, 2025 covering the sale of up to 42,393,855 43,576,075 shares of our common stock, which includes 489,269 492,407 shares of our common stock issuable upon the exercise of warrants that were owned by the Baker Entities as of May 16, 2022, April 30, 2025, and which represented approximately 26 percent of our outstanding shares at the time.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Additionally, we have contracted with Siegfried AG to manufacture API to be used in the manufacture of NUPLAZID drug product for commercial use, Corden Pharma Bergamo S.p.A. and Corden, FIS and Flamma to manufacture API to be used in the manufacture of DAYBUE drug product for commercial use.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If any third party in our supply or distribution chain for materials or finished product is adversely impacted by geopolitical and macroeconomic developments, including rapid changes in U.S. trade policy, such as the imposition of tariffs and trade barriers as well as potential retaliatory measures taken by other governments, our supply chain may be disrupted, limiting our ability to manufacture, test and distribute our products for commercial sales and our product candidates for our clinical trials and research and development operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our ability to generate product revenues will be diminished if coverage for our products from commercial or government payors is not provided, is decreased or if patients have unacceptably high out-of-pocket requirements.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Until September 2025 we had been developing the product candidate ACP-101 (intranasal carbetocin) for the treatment of hyperphagia in PWS, a neuro rare disease. In September 2025, we announced top-line results from our COMPASS PWS study, a Phase 3 study evaluating the efficacy and safety of ACP-101 for the treatment of hyperphagia in PWS. In the study, ACP-101 did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), nor was there separation from placebo on any secondary endpoint. As a result, we do not intend to investigate ACP-101 any further.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Our provision for income taxes, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflect our best assessment of estimated future taxes to be paid. Judgments and estimates based on interpretations of existing tax laws or regulations are required in determining our provision for income taxes. Changes in tax laws, regulations, or statutory tax rates, and estimates of our future taxable income could impact the deferred tax assets and liabilities provided for in the consolidated financial statements and would require an adjustment to the provision for income taxes. Prior to fiscal year 2025, we maintained a full valuation allowance against our net deferred tax assets (DTAs) due to a history of cumulative losses. However, during the fiscal year ended December 31, 2025, we achieved cumulative three-year profitability. Management determined there is sufficient positive evidence to conclude it is “more likely than not” that deferred taxes are realizable. We therefore reduced the valuation allowance accordingly.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, President Trump signed into law the OBBBA. The OBBBA made permanent key elements of the Tax Cuts and Jobs Act, including domestic research cost expensing, the business interest limitation, and 100% bonus depreciation. We evaluated the enacted effects of the legislation on our estimated annual effective tax rate and cash tax position. We expect to realize significant cash tax savings in tax year 2025 as we are no longer required to capitalize our domestic research and experimental costs under Section 174 of the Internal Revenue Code beginning with the tax year ending December 31, 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Rebates: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare Part D prescription drug benefit. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements with, or statutory requirements pertaining to, Medicaid and
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Our provision for income taxes, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflect our best assessment of estimated future taxes to be paid. Judgments and estimates based on interpretations of existing tax laws or regulations in the United States and the numerous foreign jurisdictions where we are subject to income tax are required in determining our provision for income taxes. Changes in tax laws, regulations, or statutory tax rates, and estimates of our future taxable income could impact the deferred tax assets and liabilities provided for in the consolidated financial statements and would require an adjustment to the provision for income taxes.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The company evaluates the realizability of DTAs on a quarterly basis, weighing positive and negative evidence to determine if it is “more likely than not” that all or some portion of the DTAs will be realized. The weight given to evidence is based on the extent to which it can be objectively verified.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Prior to fiscal year 2025, we maintained a full valuation allowance against our net DTAs due to a history of cumulative losses. However, during the fiscal year ended December 31, 2025, we achieved cumulative three-year profitability. Management determined there is sufficient positive evidence to conclude it is “more likely than not” that deferred taxes of $249.9 million are realizable. We therefore reduced the valuation allowance accordingly.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not to be sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Research and development expenses increased to $328.8 million for the year ended December 31, 2025 from $303.2 million for the year ended December 31, 2024. The increase in research and development expenses during 2025 was primarily related to increased expenditures for remlifanserin and other early-stage product candidates as well as increased personnel expenses, offset by reduced expenditures for ending studies that took place in 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
We are a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in CNS disorders and rare diseases.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Because we maintain a full valuation allowance against our net deferred tax assets, income tax expense is expected to primarily consist of current federal and state tax expense as a result of taxable income anticipated or incurred in certain jurisdictions. Income tax expense may fluctuate from quarter to quarter due to adjustments related to non-recurring transactions, timing of revenue and expense across different tax jurisdictions and changes in certain tax assessments.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
The increase in net product sales of NUPLAZID of $32.0 $70.7 million was due to the growth in NUPLAZID unit sales as well as a higher average net selling price in of NUPLAZID in 2023 2025 compared to 2022. 2024, partially offset by an unfavorable gross-to-net adjustments of approximately $11.8 million related to Medicare inflation cap rebates for the sales related to October 1, 2022 to December 31, 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Utilizing the actual direct costs to manufacture DAYBUE prior to receiving FDA approval, had If the previously expensed inventory been capitalized and recognized when sold, the total cost of sales with these manufacturing costs included for the year ended December 31, 2023 2025 would have increased by approximately $9.4 million. $6.3 million based on the actual direct costs to manufacture DAYBUE prior to receiving FDA approval.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease in net cash provided by operating activities in 2023 2025 relative to 2022 2024 was primarily due to increased research and development costs and sales and marketing costs, partially offset by an increase in our net revenues and decreased research and development costs, partially offset by increased sales and marketing costs. revenues.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by operating activities was $109.8 million in 2025 compared to $157.7 million in 2024 compared to net cash provided by operating activities of and $16.7 million in 2023 and net cash used in operating activities of $114.0 million in 2022. 2023.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in investing activities totaled $302.6 million in 2025 compared to net cash used in investing activities of $30.5 million in 2024 compared to and net cash provided by investing activities of $32.0 million in 2023 and net cash provided by investing activities of $73.2 million in 2022. 2023.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in selling, general and administrative expenses was primarily driven by increased marketing costs related to our consumer activation program to support the NUPLAZID and the planned expansion of the DAYBUE franchises in the U.S. and investments to support commercialization of DAYBUE outside the U.S. team.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We have several product candidates in earlier stages of development for the treatment of CNS disorders neurological and rare diseases, including ACP-711 for the treatment of essential tremor, for which we expect to initiate a Phase 2 study in 2026. diseases.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
In November 2023, the fourth quarter of 2025, we initiated a Phase 2 study evaluating the efficacy and safety of ACP-204 ACP-211 for the treatment of hallucinations and delusions associated with ADP. major depressive disorder.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of product sales was $89.0 million and $81.8 million for the years ended December 31, 2025 and $41.6 million in 2024 and 2023, 2024, respectively, or approximately 8% and 9% and 6% of net product sales, respectively.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We anticipate that the level of cash used in our operations will fluctuate in future periods depending on the levels of spending required for our ongoing and planned commercial activities for our products, our ongoing and planned development activities for pimavanserin for the negative symptoms of schizophrenia, ACP-101 remlifanserin as a treatment for PWS ADP and ACP-204 as a treatment for ADP, LBDP, studies to be conducted pursuant to our PMRs, our ongoing and planned development activities for other early- and late-stage product candidates and strategic business development to further expand our portfolio.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We expect to receive our first an invoice for rebates under the IRA from Medicare Part D unit sales for applicable period of October 1, 2024 to September 30, 2025 in 2025. June 2026.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by financing activities decreased was $49.9 million in 2025 compared to $6.8 million in 2024 compared to and $25.1 million in 2023 and $8.2 million in 2022. 2023.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new